InterCloud Reduces Convertible Debt with the sale of High Wire Business Division
Mar 01, 2017 13:02 pm UTC| Business
NEW YORK, March 01, 2017 -- InterCloud Systems, Inc. (the "Company" or "InterCloud") (NASDAQ:ICLD), a leading provider of cloud networking orchestration and automation solutions and services, today announced the sale of...
InterCloud Reduces Convertible Debt with the sale of High Wire Business Division
Mar 01, 2017 13:02 pm UTC| Business
NEW YORK, March 01, 2017 -- InterCloud Systems, Inc. (the "Company" or "InterCloud") (NASDAQ:ICLD), a leading provider of cloud networking orchestration and automation solutions and services, today announced the sale of...
InterCloud Reduces Convertible Debt with the sale of High Wire Business Division
Mar 01, 2017 13:02 pm UTC| Business
NEW YORK, March 01, 2017 -- InterCloud Systems, Inc. (the "Company" or "InterCloud") (NASDAQ:ICLD), a leading provider of cloud networking orchestration and automation solutions and services, today announced the sale of...
Alcobra to Host Investor Forum and Webcast on March 28 in New York City
Mar 01, 2017 13:01 pm UTC| Business
TEL AVIV, Israel, March 01, 2017 -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced...
Alcobra to Host Investor Forum and Webcast on March 28 in New York City
Mar 01, 2017 13:01 pm UTC| Business
TEL AVIV, Israel, March 01, 2017 -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced...
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
Mar 01, 2017 13:01 pm UTC| Business
EMERYVILLE, Calif., March 01, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the European...
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
Mar 01, 2017 13:01 pm UTC| Business
EMERYVILLE, Calif., March 01, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the European...
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood